Literature DB >> 3711219

Determination of ketoconazole in the plasma, liver, lung and adrenal of the rat by high-performance liquid chromatography.

C M Riley, M O James.   

Abstract

An accurate and precise procedure for the rapid analysis of ketoconazole in the lung, liver, plasma and adrenal gland of the rat has been developed. Separation of the drug from endogenous substances was achieved by solid-phase extraction followed by reversed-phase chromatography on a Novapak C18 column using a mobile phase of methanol--acetonitrile--0.02 M phosphate buffer (pH 6.8) (35:30:35). Depending on the tissue, the recoveries of ketoconazole and clotrimazole, which was used as an internal standard, ranged between 85.0 to 93.6% and 79.3 to 84.1%, respectively. The reproducibility of the assay was between 3 and 4%, depending on the tissue involved. The sensitivity of the procedure permitted the monitoring of ketoconazole levels for up to 24 h in the adrenal and up to 48 h for plasma, lung and liver, following oral administration of 150 mg/kg of the drug to male rats.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3711219     DOI: 10.1016/s0378-4347(00)80784-7

Source DB:  PubMed          Journal:  J Chromatogr


  6 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.

Authors:  N Brynne; C Forslund; B Hallén; L L Gustafsson; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

3.  Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver.

Authors:  D Matthew; B Brennan; K Zomorodi; J B Houston
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

4.  Effects of ranitidine and sucralfate on ketoconazole bioavailability.

Authors:  S C Piscitelli; T F Goss; J H Wilton; D T D'Andrea; H Goldstein; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

5.  Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.

Authors:  Jonatan D Lindh; Anita Annas; Lennart Meurling; Marja-Liisa Dahl; Ayman AL-Shurbaji
Journal:  Eur J Clin Pharmacol       Date:  2003-07-25       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of ketoconazole.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.